Skip to Content

Walter N. Hittelman, Ph.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX
Sophie Caroline Steves Distinguished Professorship in Cancer Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Member of Faculty, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Research Interests

Research activities in my laboratory revolve around 4 general themes.  The first theme focuses on identifying genetic/phenotypic changes associated with human multistep tumorigenesis.  These changes are translated into biomarkers and applied to tissue biopsy samples to determine individual cancer risk and response to chemopreventive intervention, especially in the aerodigestive and gastrointestinal tracts.

Education & Training

Degree-Granting Education

1972 University of California, Berkeley, CA, PHD, Biophysics
1968 University of California, Berkeley, CA, MS, Nuclear Engineering
1966 University of California, Berkeley, CA, BS, Mechanical Engineering

Postgraduate Training

8/1972-8/1974 Postdoctoral Fellowship, Cell Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, Dr. Potu N. Rao


Administrative Appointments/Responsibilities

Deputy Department Chairman, Clinical Investigation, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 1993-1999
Chief, Section of Cellular Oncology, Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 1991-2005

Honors and Awards

1999-present Sophie Caroline Steves Distinguished Professorship in Cancer Research, The University of Texas M.D. Anderson Cancer Center
1992-1999 Sophie Caroline Steves Professorship in Cancer Research, The University of Texas M.D. Anderson Cancer Center

Selected Publications

Peer-Reviewed Original Research Articles

1. Cao Y, Marks JW, Liu Z, Cheung LH, Hittelman WN, Rosenblum MG. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies. Oncogene 33(4):429-39, 1/23/2014. e-Pub 2/4/2013. PMCID: PMC4527163.
2. Gupta A, Hunt CR, Pandita RK, Pae J, Komal K, Singh M, Shay JW, Kumar R, Ariizumi K, Horikoshi N, Hittelman WN, Guha C, Ludwig T, Pandita TK. T-cell-specific deletion of Mof blocks their differentiation and results in genomic instability in mice. Mutagenesis 28(3):263-70, 5/2013. e-Pub 2/5/2013. PMCID: PMC3630520.
3. Zhou H, Ekmekcioglu S, Marks JW, Mohamedali KA, Asrani K, Phillips KK, Brown SA, Cheng E, Weiss MB, Hittelman WN, Tran NL, Yagita H, Winkles JA, Rosenblum MG. The TWEAK Receptor Fn14 Is a Therapeutic Target in Melanoma: Immunotoxins Targeting Fn14 Receptor for Malignant Melanoma Treatment. J Invest Dermatol 133(4):1052-62, 4/2013. e-Pub 11/29/2012. PMCID: PMC3600159.
4. Zimak J, Schweller RM, Duose DY, Hittelman WN, Diehl MR. Programming in Situ Immunofluorescence Intensities through Interchangeable Reactions of Dynamic DNA Complexes. Chembiochem 13(18):2722-8, 12/21/2012. e-Pub 11/20/2012. PMID: 23165916.
5. Lyu MA, Cheung LH, Hittelman WN, Liu Y, Marks JW, Cho MJ, Rosenblum MG. Bax(345)/BLyS: A novel, completely human fusion protein targeting malignant B cells and delivering a unique mitochondrial toxin. Cancer Lett 322(2):159-68, 9/28/2012. e-Pub 3/1/2012. PMID: 22388102.
6. Schweller RM, Zimak J, Duose DY, Qutub AA, Hittelman WN, Diehl MR. Multiplexed In Situ Immunofluorescence Using Dynamic DNA Complexes. Angew Chem Int Ed Engl 51(37):9292-6, 9/10/2012. e-Pub 8/15/2012. PMCID: PMC3517005.
7. Lyu MA, Pham LV, Sung B, Tamayo AT, Ahn KS, Hittelman WN, Cheung LH, Marks JW, Cho MJ, Ford RJ, Aggarwal BB, Rosenblum MG. The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma. Biochem Pharmacol 84(4):451-8, 8/15/2012. e-Pub 6/9/2012. PMID: 22687624.
8. Naguib M, Xu JJ, Diaz P, Brown DL, Cogdell D, Bie B, Hu J, Craig S, Hittelman WN. Prevention of Paclitaxel-Induced Neuropathy Through Activation of the Central Cannabinoid Type 2 Receptor System. Anesth Analg 114(5):1104-20, 5/2012. e-Pub 3/5/2012. PMCID: PMC3334436.
9. Duose DY, Schweller RM, Zimak J, Rogers AR, Hittelman WN, Diehl MR. Configuring robust DNA strand displacement reactions for in situ molecular analyses. Nucleic Acids Res 40(7):3289-98, 4/2012. e-Pub 12/11/2011. PMCID: PMC3326323.
10. Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN, Wen X, Marks JW, Cheung LH, Boland K, Li C, Adams GP, Rosenblum MG. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Mol Cancer Ther 11(1):143-53, 1/2012. e-Pub 11/16/2011. PMID: 22090420.
11. Lee J, Ryu SH, Kang SM, Chung WC, Gold KA, Kim ES, Hittelman WN, Ki Hong W, Koo JS. Prevention of Bronchial Hyperplasia by EGFR Pathway Inhibitors in an Organotypic Culture Model. Cancer Prev Res (Phila) 4(8):1306-15, 8/2011. e-Pub 4/19/2011. PMCID: PMC3151315.
12. Zhou H, Marks JW, Hittelman WN, Yagita H, Cheung LH, Rosenblum MG, Winkles JA. Development and characterization of a potent immunoconjugate targeting the fn14 receptor on solid tumor cells. Mol Cancer Ther 10(7):1276-88, 7/2011. e-Pub 5/17/2011. PMCID: PMC3523329.
13. Liu S, Chu J, Yucer N, Leng M, Wang SY, Chen BP, Hittelman WN, Wang Y. RING Finger and WD Repeat Domain 3 (RFWD3) Associates with Replication Protein A (RPA) and Facilitates RPA-mediated DNA Damage Response. J Biol Chem 286(25):22314-22, 6/24/2011. e-Pub 5/9/2011. PMCID: PMC3121378.
14. Mohamedali KA, Ran S, Gomez-Manzano C, Ramdas L, Xu J, Kim S, Cheung LH, Hittelman WN, Zhang W, Waltenberger J, Thorpe PE, Rosenblum MG. Cytotoxicity of VEGF121/rGel on Vascular Endothelial Cells Resulting in Inhibition of Angiogenesis is Mediated via VEGFR-2. BMC Cancer 11(1):358, 2011. e-Pub 8/17/2011. PMCID: PMC3176242.
15. Duose DY, Schweller RM, Hittelman WN, Diehl MR. Multiplexed and Reiterative Fluorescence Labeling via DNA Circuitry. Bioconjug Chem 21(12):2327-31, 12/15/2010. e-Pub 11/16/2010. PMCID: PMC3002180.
16. Zhou H, Liu Y, Cheung LH, Kim S, Zhang W, Mohamedali KA, Anand P, Hittelman WN, Aggarwal BB, Rosenblum MG. Characterization and mechanistic studies of a novel melanoma-targeting construct containing IκBa for specific inhibition of nuclear factor-κB activity. Neoplasia 12(10):766-77, 10/2010. PMCID: PMC2950326.
17. Robertson FM, Ogasawara MA, Ye Z, Chu K, Pickei R, Debeb BG, Woodward WA, Hittelman WN, Cristofanilli M, Barsky SH. Imaging and analysis of 3D tumor spheroids enriched for a cancer stem cell phenotype. J Biomol Screen 15(7):820-9, 8/2010. e-Pub 7/16/2010. PMID: 20639504.
18. Sun H, Li DP, Chen SR, Hittelman WN, Pan HL. Sensing of Blood Pressure Increase by Transient Receptor Potential Vanilloid 1 Receptors on Baroreceptors. J Pharmacol Exp Ther 331(3):851-9, 12/2009. e-Pub 9/2/2009. PMCID: PMC2784714.
19. Riesterer O, Mason KA, Raju U, Yang Q, Wang L, Hittelman WN, Ang KK, Milas L. Enhanced response to C225 of A431 tumor xenografts growing in irradiated tumor bed. Radiother Oncol 92(3):383-387, 9/2009. e-Pub 8/18/2009. PMID: 19695723.
20. Hu L, Hittelman W, Lu T, Ji P, Arlinghaus R, Shmulevich I, Hamilton SR, Zhang W. NGAL decreases E-cadherin-mediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells. Lab Invest 89(5):531-548, 5/2009. e-Pub 3/23/2009. NIHMSID: NIHMS93950.
21. Neal CL, Yao J, Yang W, Zhou X, Nguyen NT, Lu J, Danes CG, Guo H, Lan KH, Ensor J, Hittelman W, Hung MC, Yu D. 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res 69(8):3425-3432, 4/15/2009. e-Pub 3/24/2009. PMCID: PMC2671640.
22. Milas L, Hittelman WN. Cancer stem cells and tumor response to therapy: current problems and future prospects. Semin Radiat Oncol 19(2):96-105, 4/2009. PMID: 19249647.
23. Papadimitrakopoulou V, Izzo JG, Liu DD, Myers J, Ceron TL, Lewin J, William WN, Atwell A, Lee JJ, Gillenwater A, El-Naggar A, Wu X, Lippman SM, Hittelman WN, Hong WK. Cyclin D1 alterations and cancer development in a chemoprevention trial in laryngeal premalignancy. Cancer Prev Res (Phila) 2(1):14-21, 1/2009. PMID: 19139013.
24. Cox JD, Giralt SA, Veazie ML, Ajani JA, Bruner JM, Chan KW, Hittelman WN, Hunt KK, Iyer RB, Karp DD, Kuban DA, Lippman SM, Raad II, Rodriguez-Bigas MA, Zwelling LA, Markman M. Evaluating Quality in Clinical Cancer Research: The M.D. Anderson Cancer Center Experience. Oncology 77(2):75-81, 2009. e-Pub 7/1/2009. PMCID: PMC2790774.
25. Hittelman WN, Liu DD, Kurie JM, Lotan R, Lee JS, Khuri F, Ibarguen H, Morice RC, Walsh G, Roth JA, Minna J, Ro JY, Broxson A, Hong WK, Lee JJ. Proliferative changes in the bronchial epithelium of former smokers treated with retinoids. J Natl Cancer Inst 99(21):1603-1612, 11/7/2007. e-Pub 10/30/2007. PMID: 17971525.
26. Izzo JG, Luthra R, Wu TT, Correa AM, Luthra M, Anandasabapathy S, Chao KS, Hung MC, Aggarwal B, Hittelman WN, Ajani JA. Molecular Mechanisms in Barrett's Metaplasia and its Progression. Semin Oncol 34(2 Suppl 1):S2-6, 4/2007. NIHMSID: NIHMS22544.
27. Izzo JG, Wu TT, Wu X, Ensor J, Luthra R, Pan J, Correa A, Swisher SG, Chao CK, Hittelman WN, Ajani JA. Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. J Clin Oncol 25(6):698-707, 2/20/2007. PMID: 17308274.
28. Lyu MA, Cheung LH, Hittelman WN, Marks JW, Aguiar RC, Rosenblum MG. The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA. Mol Cancer Ther 6(2):460-70, 2/2007. e-Pub 1/31/2007. PMID: 17267661.

Invited Articles

1. Hittelman WN, Liao Y, Wang L, Milas L. Are cancer stem cells radioresistant? Future Oncol 10(10):1563-1576, 10/2010. PMCID: PMC3059151.
2. Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A, Workshop Program Committee. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark 3(1):1-33, 2007. PMID: 17655039.

Grant & Contract Support

Title: Mechanisms and Consequences of NOTCH Dysfunction in Head and Neck Cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Mitchell J. Frederick
Duration: 1/1/2015 - 12/31/2018
Title: Predicting and overcoming chemoradioresistance in p53-mutant head and neck cancer
Funding Source: NIH/NIDCR
Role: Co-Investigator
Principal Investigator: Jeffrey N. Myers
Duration: 7/20/2014 - 5/31/2019
Title: Signs of inflammatory breast cancer are caused by stromal field effects
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Wendy Woodward
Duration: 9/17/2013 - 6/30/2017

Last updated: 3/14/2016